Kerrisdale Advisers LLC Takes Position in Establishment Labs Holdings Inc. $ESTA

Key Points

• Kerrisdale Advisers bought 20,390 shares of Establishment Labs worth approximately $1.75 million, while institutional investors collectively own 72.91% of the company.
• Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above estimates, but its adjusted loss of $0.39 per share missed expectations.
• Analyst sentiment remains generally positive: eight analysts rate the stock a Buy, one rates it a Sell, and the average price target is $100.25 versus a recent share price of $70.64.

Kerrisdale Advisers LLC bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,390 shares of the company's stock, valued at approximately $1,750,000. Kerrisdale Advisers LLC owned 0.07% of Establishment Labs at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ESTA. BlackRock Inc. acquired a new stake in Establishment Labs in the second quarter worth about $135,752,000. William Blair Investment Management LLC acquired a new position in Establishment Labs during the 2nd quarter valued at about $61,273,000. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the 2nd quarter worth about $52,176,000. Rice Hall James & Associates LLC bought a new stake in shares of Establishment Labs during the 2nd quarter worth about $48,134,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company's stock worth $59,145,000 after buying an additional 438,206 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

Establishment Labs Stock Performance

Shares of ESTA opened at $70.64 on Monday. The company has a 50-day moving average of $85.00 and a two-hundred day moving average of $74.94. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -53.92 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm's quarterly revenue was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.57) EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Citigroup upgraded shares of Establishment Labs from a "neutral" rating to a "buy" rating and set a $92.00 price objective for the company in a report on Thursday, August 13th. Weiss Ratings reissued a "sell (e+)" rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Mizuho upped their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. Needham & Company LLC lifted their target price on Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, BTIG Research boosted their price target on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Establishment Labs currently has an average rating of "Moderate Buy" and an average price target of $100.25.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source